Actavis, Inc. (NYSE:ACT)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.


Player Avatar Herbstmd (51.13) Submitted: 8/23/2014 5:37:14 PM : Underperform Start Price: $226.76 ACT Score: -13.85

Way overpriced. Buys up other successful companies, then fires everyone in them with any experience, keeping only the youngest most inexperienced staff. I think this will prove in the long run to be a serious weakness. Overbearing company culture that cares little for employees.

Featured Broker Partners